The American Heart Association and the Heart Failure Society of America estimate that more than 5 million Americans have been diagnosed with heart failure and that 500,000 more diagnoses are made each year. Heart failure is the leading cause of hospital admissions in the U.S. Only about half of Americans diagnosed with heart failure will survive more than five years. Each year, more than 300,000 people die from the condition.
"The potential effects of this study and the HeartNet hold tremendous promise," said Robert M. Mentzer Jr., M.D., dean of the Wayne State University School of Medicine and senior advisor to the president for medical affairs. Dr. Mentzer, a nationally recognized cardiothoracic surgeon who has performed numerous heart transplants, serves as co-principal investigator of the clinical research study, along with Salik A. Jahania, M.D., a cardiothoracic surgeon with the Wayne State University Physician Group and Oakwood Healthcare System. Dr. Jahania performed the procedure.
"More research is needed, but the HeartNet appears to offer the possibility of not only halting but potentially reversing congestive heart failure," Dr. Mentzer said. "The implant could reduce the need for heart transplants among some patients."
Along with Drs. Mentzer and Jahania, Peter Vitkevicius, M.D., and Arthur Riba, M.D., were instrumental in identifying and evaluating patients for the purposes of the study.
The investigational HeartNet is a mesh constructed of nitinol, a
nickel-titanium alloy. Because the device conforms to the shape of the
heart -- expand
|SOURCE Oakwood Healthcare System; Wayne State University Schoolof Medicine|
Copyright©2008 PR Newswire.
All rights reserved